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Abstract 
Background: Concern exists about the safety of iron supplementation given to individuals in malarious areas. The 
possible unfavourable impact of iron supplementation on malaria might be less when slow-release iron compounds 
are used instead of ferrous salts, because no toxic non-transferrin bound iron is formed. The aim of this study was to 
determine the effect of iron supplementation using the slow-release iron compound iron polymaltose (IPM) on the 
acquisition of malarial parasitaemia.
Methods: A randomized, placebo-controlled trial was performed in schoolchildren aged 5–18 years with mild or 
moderate anaemia on the Indonesian island Flores. Microscopic malaria-negative children were randomized to 
receive 8 weeks of IPM (6 mg elemental iron/kg/day) or placebo . The primary outcomes were the occurrence of 
microscopically detectable malarial parasitaemia at week 4, 8, 12 and 16 after start of treatment and the proportion of 
participants with real-time (RT) PCR positive malarial parasitaemia at week 16.
Results: 294 Children were assigned to the IPM group and 297 to the placebo group. Whereas IPM supplementation 
failed to increased haemoglobin or ferritin concentrations, the IPM group had a significantly higher rate of occur-
rence of microscopically detectable parasitaemia [hazard ratio 2.2, 95% C.I. 1.2–4.0; P = 0.01]. This higher rate was 
confined to iron-replete children. At the end of the study, 89% of the children in the IPM group had remained free 
from microscopically detectable parasitaemia vs 95% of children in the placebo group. The proportion of plasmodial 
RT-PCR positive children was similar in both groups at week 16 (IPM group 16.6% vs placebo group 14.3%; P = 0.47). 
When analysis was restricted to iron-replete children (serum ferritin ≥30 µg/l), there was a trend for a higher propor-
tion being RT-PCR positive at week 16 in the IPM group compared with the placebo group (20 vs 13.3%; P = 0.07). 
Erythrocyte microcytosis was an independent risk factor for microscopically detectable malarial parasitaemia.
Conclusions: A short course of IPM should be used cautiously in anaemic children in malaria endemic areas, as it 
has limited efficacy in treating iron deficiency, while it increases the rate of microscopic malarial parasitaemia in those 
with replete iron stores.
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Background
Iron deficiency is highly prevalent in children in large 
parts of the world and is associated with anaemia and 
negative effects on immune function and cognitive devel-
opment [1]. There has been an ongoing debate on the risk 
benefit ratio of iron supplementation in malaria endemic 
regions [2–5], especially following publication of the 
results from the Pemba trial, which showed increased 
risk for hospitalization and mortality after untargeted 
iron supplementation with a low daily iron dose (12.5 mg) 
among iron-replete children [6].
It is common practice among physicians in many parts 
of the world to prescribe a short course of iron in a thera-
peutic dosage to children with anaemia. Whether this 
practice is associated with an increased risk for malaria 
is unknown, especially in malaria-endemic areas outside 
sub-Saharan Africa where malaria caused by Plasmodium 
vivax is more common, malaria transmission is generally 
less intense and clinical malaria is more frequently seen 
in older children.
Slow-release iron compounds such as iron polymalt-
ose (IPM) or sodium iron ethylenediaminetetraacetate 
(NaFeEDTA) are frequently used for iron supplemen-
tation instead of ferrous salts in Asian countries. These 
compounds may have a less unfavourable effect on 
malaria, as they do not produce toxic non-transferrin 
bound iron (NTBI) [7–9]. However data on the effec-
tiveness of these compounds in correcting iron defi-
ciency have been conflicting with some studies showing a 
favourable [10], but others a poor haematologic response 
[11–13].
The aim of our study was to investigate the effect of a 
short course of IPM on the risk for microscopic and real-
time (RT) PCR positive malarial parasitaemia in anae-
mic school-aged children with a negative malaria blood 
slide on Flores Island, Indonesia. Including the number 
of PCR positive children is relevant as malaria parasite 
densities in (semi-) immune individuals are frequently 
below the microscopic detection limit. Secondary objec-
tives were to determine the effects of IPM on haemoglo-
bin (Hb) concentrations and iron status, to determine 
the influence of baseline iron status and mean cell vol-
ume (MCV) on the risk for malarial parasitaemia and the 
risk of children with submicroscopic malaria to develop 
microscopic parasitaemia.
Methods
Study area
Nangapanda village, Ende district, East Nusa Tenggara 
Province, Flores Island, Indonesia is a semi-urban village 
consisting of 18 sub-villages with an estimated popula-
tion of 22,000 residents. It has a humid climate with an 
average yearly rainfall of around 1.800 mm and on aver-
age 82 rainy days. The rainy season lasts from Novem-
ber until April with a peak in rain during December to 
March. The primary general health care services are pro-
vided in a local Puskesmas (health centre). Plasmodium 
falciparum and Plasmodium vivax transmission in this 
area is stable enough to induce clinical immunity [14]. A 
population based survey using real-time PCR in the dry 
season in 2008 showed a prevalence of P. falciparum, P. 
vivax, and Plasmodium malariae of 14.5, 13.2, and 1.9% 
respectively [14]. Sub-microscopic parasitaemia was 
found in more than 80% of all positive cases. Intestinal 
helminth infections also have a high prevalence in this 
area [15].
Trial design, participants and interventions
This study was designed as a prospective double blind 
placebo-controlled randomized trial. It was conducted 
between July 2011 and January 2012. Children aged 
5–18  years were recruited from twenty-one schools in 
Nangapanda area. Inclusion criteria were a negative 
malaria blood slide and mild anaemia, defined as a Hb 
level 8–11.4 g/dl in children below 7 years old, Hb level 
8–11.9 g/dl for girls ≥7 years old and Hb 8–12.9 g/dl for 
boys ≥7 years old. These cut off levels were based on the 
2011 criteria used by the Indonesian national govern-
ment referral hospital Cipto Mangunkusumo. Exclusion 
criteria were clinical symptoms suggestive of malaria or 
any other underlying medical condition.
Enrolled children were treated with the anthelminthic 
drug albendazole (PT Indofarma Pharmaceutical, Band-
ung, Indonesia) 400 mg OD for three consecutive days. 
Subsequently, they were randomized in a 1:1 ratio to 
receive either iron(III)-hydroxide polymaltose complex 
(Maltofer®, Combiphar, Bandung, Indonesia) or pla-
cebo, both taken 6 days a week for 8 consecutive weeks. 
The iron(III)-hydroxide polymaltose complex tablets 
of 357 mg contain 100 mg of elemental iron. A weight-
based dosage was used aiming at a daily dose of elemen-
tal iron of 6 mg/kg daily. Randomization (simple random 
allocation) was performed using a computer-generated 
randomization list. The randomization list was created 
by researchers not involved in this trial, and the study 
doctors handed out the study medication using this 
list. Trial participants and laboratory personnel were 
blinded for treatment assignment; the study doctor was 
not blinded. The treatment phase started approximately 
4 weeks after administration of albendazole and was fol-
lowed by a follow up phase of another 8 weeks. Teach-
ers handed out the study medication on a daily basis and 
documented compliance under supervision of the study 
clinician.
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Follow‑up, outcome measures and sample sizes
Children were followed for 96 days (16 weeks) and were 
reviewed by study clinicians at week 0, 4, 8, 12, and 16 
following start of IPM or placebo. These study visits 
included measurement of body temperature and collec-
tion of venous blood, which was used for a full blood 
count, malaria slide (week 0, 4, 8, 12 and 16) and real-
time PCR detection of malarial parasitaemia and serum 
ferritin concentrations (latter two at week 0 and 16). The 
primary outcome measure was the detection of micro-
scopically positive malarial parasitaemia at one of the 
four time points and the number of RT-PCR positive chil-
dren at week 16. Secondary outcome measurements were 
the change in Hb and ferritin concentration and MCV 
value. Malaria slides were examined after the study had 
ended and results had therefore no clinical consequences 
for the participating children. With the exception of the 
full blood count, the other laboratory examinations were 
also performed after ending of the study. Children with 
any sign of illness during the study were referred to the 
Puskesmas.
Laboratory procedures and definitions
Presence of microscopic parasitaemia was examined by 
Giemsa staining of both thin and thick blood smears at 
the Department of Parasitology, University of Indone-
sia. An aliquot of 200  μl stored whole blood was used 
for Plasmodium DNA isolation, prior to real-time PCR 
detection using Plasmodium-specific primers and species 
specific probes, as previously described [16]. Haemocy-
tometry was performed using a Sysmex haematologi-
cal analyzer KX-21  N (Sysmex, Kobe, Japan). A MCV 
value below 75 fl represented microcytosis. The Mentzer 
index, which is the ratio between MCV and RBC count, 
was used as a screening test for thalassaemia using a cut 
off level <13 being suggestive for thalassaemia [17]. Iron 
deficiency was defined as ferritin level  <30  µg/l, as rec-
ommended by the World Health Organization in malaria 
endemic regions [18].
Ethics
The study was approved by the ethical committee from 
the Faculty of Medicine, University of Indonesia (Ref: 96/
PT02.FK/ETIK/2010) and all procedures followed were 
in accordance with the Helsinki Declaration. Parents 
or caretakers of all children provided written informed 
consent.
Statistical analysis
The sample size was calculated to detect a 1.5 hazard 
ratio (HR) in the IPM group with α  =  0.05 and power 
of 90%. Baseline data are expressed as mean (standard 
deviation) or median (interquartile range), depending 
on whether data were normally distributed or as number 
(%). Differences in the characteristics between the inter-
vention and placebo groups were evaluated by stand-
ard statistical methods. Overall cumulative probability 
to remain free of microscopic parasitaemia during the 
study period of 16  weeks was assessed by the Kaplan–
Meier method and log-rank statistics using an intention 
to treat approach. Children were censored from the point 
at which they acquired the first episode of microscopic 
parasitaemia. Children presenting to the Puskesmas were 
also censored from the time of presentation. Differences 
in the proportion of RT-PCR positive children in the IPM 
and placebo group at week 16 were compared using Chi 
square tests. Exploratory subgroup analyses were also 
performed for participants separated on the basis of iron 
status and baseline MCV value. Unadjusted and adjusted 
HRs and 95% CI were calculated using Cox proportional 
hazards model with iron deficiency, age, sex and micro-
cytosis as covariates. The first covariates were pre-spec-
ified, the latter (microcytosis) was added later after it 
was found to be independently associated with outcome. 
Data were recorded in MS Access (Microsoft Inc.,) and 
exported for analysis in SPSS 21.0 (SPSS Inc., Chicago, 
Ill). A P value <0.05 signified statistical significance.
Results
Baseline characteristics
Figure  1 shows details on the enrolment and follow-
up. Data from 591 schoolchildren, of whom 294 were 
assigned to the IPM group and 297 to the placebo group, 
were analysed according to intention to treat. The mean 
age was 10 years with range of 5–18 years and 76% chil-
dren were male. Baseline characteristics of the children 
assigned to the two groups were similar (Table 1), includ-
ing gender, age distribution, weight and values of Hb, 
ferritin and MCV. Overall, the number of children with 
a positive PCR for malaria was low (5.8%), with a signifi-
cantly higher proportion of children with a positive P. fal-
ciparum PCR in the placebo group than in the iron group 
(3.7 vs 1.0%; P = 0.03). Because of the low prevalence of 
submicroscopic parasitaemia at baseline, the PCR results 
for P. falciparum and P. vivax were combined (referred to 
as PCR Plasmodium) for further analyses. The propor-
tion of children with absolute iron deficiency, defined as a 
serum ferritin level below 30 µg/l or 12 µg/l, was 26.9 and 
8.6%, respectively. In contrast, microcytosis, defined as a 
MCV value below 75 fl, was present in over half (54.3%) 
of children. Using the Mentzer index (ratio MCV/RBC 
count below 13) as a screening test for thalassemia, this 
condition appeared common with an estimated overall 
prevalence of 23.0%.
A total of 13 children (10 from IPM group and 3 pla-
cebo group) were seen in between the regular study 
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visits at the local health centre because of different clini-
cal symptoms (Additional file 1). They were not reviewed 
in a systematic way. Fever was among the symptoms in 4 
children in the IPM group and one child in the placebo 
group. Because a final diagnosis was not established in 
these children and malaria diagnostics were not per-
formed, they were censored from the time-point they 
presented to the local health centre.
Effect of IPM on Hb and ferritin concentrations
Table  2 shows data of Hb, ferritin and MCV at week 
16 and the change in these parameters from baseline. 
Changes in values of Hb, serum ferritin and MCV were 
small and similar in both groups. Even in the subgroup 
of children with absolute iron deficiency at baseline, the 
increase in serum ferritin was small and similar between 
the groups. There was also no difference in the propor-
tion of children remaining iron deficient at week 16 
between the IPM and placebo groups.
Effect of IPM on microscopically detectable parasitaemia
Figure 2 shows that children assigned to the IPM group 
had a significantly higher rate of development of micro-
scopically detectable parasitaemia than those assigned to 
the placebo group (unadjusted hazard ratio (HR) 2.2, 95% 
CI 1.2–4.0; P = 0.01). The cumulative number of children 
developing microscopic positive parasitaemia between 
week 0 and 16 was 29 (19 P. falciparum, 10 P. vivax) in the 
IPM group and 14 (8 P. falciparum, 6 P. vivax) in the pla-
cebo group. At the end of the study, 89% of the children 
in the IPM group had remained free from microscopi-
cally detectable parasitaemia vs 95% of children in the 
placebo group. Seven children had fever (≥38 °C) at one 
of the four regular study visits time; three of these chil-
dren had a positive malaria slide on the same time point. 
Exploratory analysis showed that when children were 
stratified by iron status, the increased rate of microscopic 
malaria in the IPM group was due to the increased rate in 
children who were iron replete (serum ferritin ≥30 μg/l) 
Fig. 1 Trial overview and study structure
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at baseline (Fig.  2b). Iron deficient children in the IPM 
group had a similar incidence of microscopically detect-
able parasitaemia as children in the placebo group (95% 
of children free of parasitaemia during study). When 
children were stratified by MCV category, those with 
microcytosis (MCV value  <75  fl) had the highest rate 
of developing microscopically detectable parasitaemia 
(Fig.  2c). Univariate and multivariate adjusted hazard 
ratio for the first episode of microscopic malaria were 
also calculated using Cox regression with treatment arm, 
baseline iron status, baseline MCV value and age as vari-
ables (Table 3). Assignment to the iron group and micro-
cytosis were independently associated with an increased 
rate of microscopic malaria, while baseline iron status 
and age were not.
The effect of IPM on PCR‑based detection of malaria
From the children with submicroscopic malaria at 
baseline (16 in the iron group and 18 in the placebo 
group), only 3 developed microscopically detectable 
parasitaemia during follow up (2 in the IPM group 
and 1 in the placebo group). At the end of the study, 5 
children in the IPM group and 7 in the placebo group 
had remained PCR positive for Plasmodium. Results 
of the Plasmodium PCR at week 16 were available in 
278 of children in the IPM group and 286 of children 
in the placebo group and are summarized in Table  4. 
A positive PCR result was found in 46 (16.6%; 23 P. 
falciparum, 18 P. vivax, 5 mixed infection) of children 
in the IPM group and in 41 (14.3%; 23 P. falciparum, 
14 P. vivax, 4 mixed infection) in the placebo arm 
(P  =  0.47). Analysing only iron-replete children, we 
found that 41 (20.0%; 20 P. falciparum, 16 P. vivax, 5 
mixed infection) out of 205 children in the IPM group 
and 28 (13.3%; 15 P. falciparum, 10 P. vivax, 3 mixed 
infection) out of 210 children in the placebo group 
(P  =  0.07) were PCR Plasmodium positive. Overall, 
a higher proportion of children with microcytosis at 
baseline had a positive Plasmodium PCR at week 16 
Table 1 Baseline characteristics of  the 591 children 
from Flores island, Indonesia
a Differences in distribution of baseline characteristics were analysed using 
the Chi square test or Student t test using log transformed data. There were 
no statistically significant differences between except in number of number 
with positive PCR Plasmodium falciparum (P = 0.03), number of children with 
ferritin level < 12 µg/l) (P = 0.03) and number of children with serum ferritin 
level < 12 µg/l and microcytosis (P = 0.03)
b Suspected thalassemia was defined as Mentzer index (MI) < 13, the ratio of 
(MCV/RBC)
IPM iron polymaltose, IQR interquartile range, PCR polymerase chain reaction
Variablea IPM group Placebo group
Number 294 297
Gender, male, n (%) 225 (77) 224 (75)
Age, years, mean ± SD 10.2 ± 2.8 10.5 ± 3.0
 Baseline age 5–11, n (%) 206 (70) 190 (64)
 Baseline age 12–15, n (%) 59 (20) 72 (24)
 Baseline age 16–18, n (%) 29 (10) 35 (12)
Weight, kg, mean ± SD 24.8 ± 8.1 26 ± 9.7
PCR Plasmodium, n (%) 16 (5.4) 18 (6.1)
 PCR P. falciparum, n (%) 3 (1.0) 11 (3.7)
 PCR P. vivax, n (%) 13 (4.4) 7 (2.4)
Haemoglobin concentration, g/dl, 
mean ± SD
12.0 ± 0.8 12.0 ± 0.9
Haematocrit, mean ± SD 37.4 ± 3.1 37.7 ± 2.5
Mean corpuscular volume (MCV), fl, 
mean ± SD
74.2 ± 5.5 73.7 ± 5.7
 MCV < 75 fl, n (%) 147 (52) 164 (57)
 MCV ≥ 75 fl, n (%) 147 (48) 132 (43)
Ferritin concentration, µg/l, median 
(IQR)
43.5 (28.3–
64.8)
40.4 (26.6–64.2)
Number with ferritin < 30 µg/l, n (%) 77 (26) 82 (28)
 With MCV < 75 fl, n (%) 39 (13) 52 (18)
 With MCV ≥ 75 fl, n (%) 38 (13) 29 (10)
Number with ferritin < 12 µg/l, n (%) 18 (6) 33 (11)
 With MCV < 75 fl, n (%) 6 (2) 21 (7)
 With MCV > 75 fl, n (%) 12 (4) 11 (4)
Suspected thalassaemia, n (%)b 62 (21) 74 (25)
Table 2 Haemoglobin, ferritin and  MCV values at  end 
of study
There were no statistical significant differences in any parameter between the 
groups
a Iron deficiency defined as serum ferritin concentration < 30 μg/l
b Microcytosis defined as MCV ≤ 75 fl
∆ = Mean or median change between baseline and week 16
Variable IPM group Placebo group
Haemoglobin level available, n 290 288
 Haemoglobin level, g/dl, 
mean ± SD
12.1 ± 1.0 12.0 ± 1.1
 ∆ Haemoglobin, g/dl, mean ± SD 0.09 ± .91 0.08 ± .85
Ferritin level available, n 277 276
 Ferritin level, µg/l, median (IQR) 47.7 (30.8–70.4) 45.2 (28.8–65.8)
 ∆ Ferritin, µg/l, median (IQR) 3.0 (−9.9 to 17.7) 1.3 (−9.4 to 14.6)
Children with iron deficiency at 
baseline, na
77 82
 Children remaining iron deficient 
at wk 16, n (%)
43 (55.8) 53 (64.6)
 ∆ Ferritin, µg/l, median (IQR) 6.1 (2.6–17.5) 5.9 (−0.1 to 14.5)
Mean corpuscular volume (MCV) 
available, n
290 288
 MCV, fl, mean ± SD 74.7 ± 5.4 74 ± 5.6
 ∆ MCV, fl, mean ± SD 0.5 ± 2.2 0.4 ± 1.9
Children with microcytosis at 
baseline, nb
147 164
 Persistent microcytosis at wk 16, 
n (%)
133 (87.5) 148 (87.6)
 ∆ MCV, fl, mean ± SD 1.1 (0.7–1.5) 0.7 (0.4–1.1)
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compared with children with a normal MCV value 
(19.3 vs 9.3%; P =  0.001). However, in the subgroups 
of children with or without microcytosis, the propor-
tion of Plasmodium PCR positive children was similar 
in the IPM and placebo arms.
Discussion
The main findings of this study are that a short course 
(8  weeks) of therapeutic iron supplementation using 
the slow release iron compound IPM was ineffec-
tive in raising Hb or ferritin levels in anaemic Indone-
sian schoolchildren, whereas it did increase the risk for 
Fig. 2 Kaplan-Meier plots for the first episode of microscopic malaria in the whole group (a) and aggregated by iron status (b) and mean corpuscu-
lar volume (MCV) (c). Statistical comparison was performed with long-rank test with Bonferroni correction. IPM iron polymaltose
Table 3 Univariate and multivariate adjusted hazard ratio 
for the first episode of microscopic malarial parasitaemia
Microcytosis defined as MCV value < 75 fl; iron deficiency as ferritin 
concentration < 30 µg/l. Age was included as continuous variable
HR hazard ratio, CI confidence interval
Variable Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Iron treatment 2.2 (1.2–4.2) 0.013 2.3 (1.2–4.3) 0.012
Microcytosis 3.3 (1.6–7.1) 0.001 3.4 (1.7–7.1) 0.001
Iron deficiency 0.6 (0.3–1.3) 0.18 0.6 (0.3–1.4) 0.22
Age 0.9 (0.8–1.0) 0.22 1.0 (0.9–1.1) 0.63
Female sex 1.3 (0.7–2.5) 0.43 1.7 (0.9–3.2) 0.13
Table 4 Number (proportion) of  participants with  a posi-
tive Plasmodium RT-PCR at week 16
IPM group
No. (%)
Placebo group
No. (%)
P value
Overall 46/278 (16.6) 41/286 (14.3) 0.47
Iron status baseline
 Iron replete 41/205 (20.0) 28/210 (13.3) 0.07
 Iron deficient 5/73 (12.6) 13/76 (17.1) 0.06
MCV baseline
 Microcytosis 31/143 (21.7) 31/161 (19.3) 0.60
 No microcytosis 15/135 (11.1) 10/124 (8.1) 0.41
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microscopically detectable plasmodial parasitaemia, 
as has previously been shown for ferrous salts in a for-
tification [6] and therapeutic dose [19]. Similar to find-
ings from the Pemba study [6], this increased risk was 
restricted to children who were iron-replete. Further-
more, in our study population, a low MCV value was 
independently associated with an increased incidence of 
microscopically detectable parasitaemia.
Worldwide, the most common method of screen-
ing individuals for iron deficiency involves measuring 
haemoglobin or haematocrit. It should be taken into 
account, however, that iron deficiency anaemia only rep-
resents the end of the spectrum of iron deficiency. Recent 
iron supplementation studies in malaria areas were gen-
erally performed in children less than 5  years old from 
sub-Saharan Africa in whom anaemia and iron deficiency 
were common. The Indonesian children enrolled in our 
study were older, and although anaemia was also rela-
tively common in the study area, it was mostly mild with 
relatively high iron stores (based on ferritin levels). In 
many low-resource areas, measuring iron status indica-
tors such as ferritin is neither affordable nor logistically 
feasible. Instead of targeted iron supplementation based 
on iron status, supplementation using safer iron com-
pounds that do not increase the risk for malaria would 
offer a valuable alternative. Unfortunately, the hypothesis 
that IPM would represent such an alternative, because it 
does not lead to the formation of NTBI in contrast to fer-
rous salts [9, 20], proved incorrect. In addition, the data 
highlight the importance of malaria prevention measures 
and prompt diagnostics and treatment of malaria when 
children are given iron supplements in malaria-endemic 
regions.
IPM also had poor effectiveness in treating iron defi-
ciency. This finding does not stand alone, as multiple 
studies have previously shown reduced or even absent 
effectiveness of IPM in correcting iron deficiency [11–13, 
21]. Iron absorption studies have also shown a signifi-
cant lower iron bioavailability of IPM compared with fer-
rous salts [22, 23], especially when taken on an empty 
stomach. This poor bioavailability was the reason that a 
high iron dose of 6 mg/kg body weight was used in our 
study, like in previous iron supplementation studies in 
children [12]. Other reasons for the low efficacy of IPM 
include the fact that moderate anaemia and absolute iron 
deficiency were relatively rare, the fact that albendazole 
was given at enrolment and the possible confounding 
effects of inflammation. The latter impairs iron absorp-
tion through the effects of the iron regulatory hormone 
hepcidin. It is possible that a proportion of children 
experienced a period of asymptomatic malarial parasi-
taemia during the course of the study. Previous studies 
have shown that asymptomatic parasitaemia increases 
hepcidin concentrations and that treatment with anti-
malarials improves iron absorption [24, 25]. Nonetheless, 
the confounding effects of malaria-associated inflamma-
tion in the present study appeared limited as children 
with patent parasitaemia were excluded from enrolment 
and the prevalence of subpatent parasitaemia was low.
The mechanisms responsible for the higher incidence 
of malarial parasitaemia in those assigned to IPM remain 
speculative, especially since a clear effect of IPM on iron 
status was absent. It is also not easy to reconcile this find-
ing with the fact that the increased malaria risk was con-
fined to iron replete children. Moreover, only a minority 
of children with submicroscopic malaria at enrollment 
developed microscopically detectable parasitaemia and 
this risk was similar in the IPM and placebo groups. As 
reviewed recently, many questions still remain on how 
exactly iron deficiency protects against malaria and how 
iron supplementation may increase the risk for malaria 
[26]. Direct use of iron by parasites, iron-related changes 
in erythropoiesis and the immune and vascular effects 
of iron deficiency and iron supplementation may all be 
involved [26]. However, other factors may also play a role. 
After intake, only a small percentage of iron is absorbed 
in the small intestine and most of the iron passes the 
colon. Recent studies indicate that iron can induce over-
growth of enteric pathogens and bowel inflammation 
[27–29] and an association between the composition of 
the stool microbiota and the prospective risk for malaria 
was recently shown [30]. These enteric effects of iron on 
malaria pathogenesis certainly warrant further study.
Whereas the Pemba trial showed an adverse effect of 
iron supplementation on malaria [6], another recent trial 
in Ghana, in an area where insecticide-treated bed nets 
and malaria treatment were readily available, showed a 
lower malaria incidence in children assigned to an iron 
containing micronutrient group, although the number 
of hospital admissions in this group was higher [31]. The 
recent WHO guideline on daily iron supplementation 
in infants and children also concludes that in malaria-
endemic areas, iron supplementation does not increase 
the risk of clinical malaria or death when regular malaria-
surveillance and treatment services are provided [32]. 
In the study area in Indonesia where this study was con-
ducted, P. vivax malaria is also common, and although 
the number of P. vivax cases was insufficient to analyse 
separately, its incidence appeared higher in the IPM 
group. This is consistent with two previous studies in 
children and pregnant women in which iron supplemen-
tation was associated with increased P. vivax burden [33, 
34].
The primary outcome in this study was microscopi-
cally or RT-PCR detectable plasmodial parasitaemia. 
It lacked sufficient power to examine clinical endpoints 
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as the development of febrile malaria was rare and only 
few clinical events were noted. Only three children with 
a positive malaria slide had a concurrent fever at the 
same time point, suggesting that most of the children 
had asymptomatic parasitaemia. The observation that 
febrile malaria appeared rare is explained by the fact that 
the study was performed in semi-immune children from 
a moderate malaria transmission area. It can also not 
be excluded that the thirteen children who visited the 
local health centre had clinical malaria. However, fever 
was only reported by five of these children and many 
had symptoms suggestive for an alternative illness than 
malaria.
The data also showed that microcytosis was indepen-
dently associated with the development of microscopic 
malaria. Although MCV has been included as a param-
eter in iron studies in malaria endemic regions [35–37], 
it was not analysed as an independent risk-factor for 
malaria. Opposite to the present findings, one might 
assume that microscopic anaemia identifies children at 
lower risk for malaria during iron treatment, as micro-
cytosis is commonly seen in iron deficiency and thalas-
saemia, conditions both considered to be associated with 
protection against clinical malaria. Unfortunately, it was 
not feasible to perform haemoglobin electrophoresis to 
diagnose thalassaemia, but based on the Mentzer index, 
thalassaemia was suspected in around 50% of children 
with microcytosis. Because MCV is part of the Mentzer 
index, it was also not feasible to assess this index as an 
independent risk factor for parasitaemia. Plasmodium 
vivax has a strong predilection for young erythrocytes, 
particularly reticulocytes, whereas P. falciparum also 
invades older and therefore more microcytic cells [38]. 
Recent in vitro studies, however, suggested that P. falci-
parum favours invasion and replication in young eryth-
rocytes as well [26]. One may speculate that infection 
of young and larger erythrocytes results in premature 
senescence and more rapid clearance from the circulation 
while senescence of infected microcytic cells is delayed.
This study has several limitations. First, the number of 
submicroscopic and microscopic malaria cases at base-
line and during the study was lower than anticipated lim-
iting the study power and the ability to analyse clinical 
malaria cases and P. vivax separately. Malaria prevalence 
studies, conducted in the years prior to start of this study, 
had shown a prevalence of parasitaemia of 26.4% [14]. 
Second, whereas laboratory personnel who performed 
the malaria diagnostics were blinded for treatment allo-
cation, the study doctor was not. Third, NTBI levels were 
also not available, partly because its correct measure-
ment is technically challenging. Fourth, children who 
fell ill were assessed in the local health centre and were 
not assessed by the study team. As mentioned earlier, it 
is therefore unknown whether malaria was the cause of 
their illness. As 10 of these children were assigned to the 
IPM arm and 3 to the placebo arm, it is unlikely that the 
conclusions from our study would change in case malaria 
was indeed the cause of the illness. Finally, ferritin lev-
els at baseline were not corrected for inflammation, 
although it is unlikely that inflammation was common in 
the participants, as those with microscopically parasitae-
mia were excluded.
Conclusions
A short course of IPM had limited efficacy in treating 
iron deficiency, but still increased the rate of occurrence 
of microscopic malarial parasitaemia. IPM is widely used 
in Asia, but the present findings add to the evidence that 
its use in anaemic children should be discouraged.
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